CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$3.26 (+94.77%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
CUMBERLAND PHARMACEUTICALS INC saw revenue fall 1.1% to $31.27M over the twelve months to Jun 30, 2026. Free cash flow was $683.90K, down 90.3% from a year earlier.
Revenue
$31.27M
-1.1% vs. a year earlier
Operating income
-$9.63M
TTM Q2 2026
Free cash flow
$683.90K
-90.3% vs. a year earlier
EPS, diluted
-$0.73
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $100.38M
- P/E ratio
- –
- Price to sales
- 3.21
- Price to book
- 5.76
- Dividend yield
- –
- Free cash flow yield
- 0.68%
Fundamentals
- Revenue
- $31.27M
- Net income
- -$10.92M
- EPS, diluted
- -$0.73
- Free cash flow
- $683.90K
- Book value per share
- $1.16
- Diluted shares
- 15M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$31.27M-1.1% YoY
Gross profit
–
Operating income
-$9.63M
Net income
-$10.92M
EPS, diluted
-$0.73
Free cash flow
$683.90K-90.3% YoY
Reported periodTrailing twelve months